Q2 2025 Veru Inc Earnings Call Transcript

May 8, 2025 / 12:00 PM GMT

Release Date Price: $5.22 (+4.15%)

Transcript 10-Q8-K

Key Points

Positve

Veru Inc (VERU) reported positive topline results from its Phase 2B clinical study, demonstrating that its drug candidate, Novosarm, significantly preserves lean body mass while promoting fat loss.
The company has sufficient cash to fund operations into the fourth quarter of the calendar year, allowing it to reach several upcoming catalysts.
Veru Inc (VERU) is actively pursuing non-dilutive funding options, including potential partnerships with large pharmaceutical companies.
The company is developing a novel modified release oral formulation of Novosarm, which is expected to be available for Phase 3 clinical studies and commercialization.
Veru Inc (VERU) plans to focus its Phase 3 clinical program on older patients, a large market population with a high prevalence of obesity and sarcopenic obesity.

Negative

Veru Inc (VERU) reported a net loss of $7.9 million for the quarter, indicating ongoing financial challenges.
The company acknowledged that its current cash reserves are not sufficient to fund operations for the next 12 months, highlighting the need for additional capital.
Research and development costs increased significantly due to expenses related to the Novosarm Phase 2B clinical study.
The sale of the FC2 female condom business resulted in a loss of approximately $4.2 million, impacting the company's financial position.
Veru Inc (VERU) faces uncertainties regarding the regulatory path forward for its drug candidates, pending further discussions with the FDA.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

VERU.OQ - Veru Inc
Q2 2025 Veru Inc Earnings Call
May 08, 2025 / 12:00PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Good morning ladies and gentlemen, and welcome to Vero Inc.s investor conference call. All participants will be in a listen-only mode. Should you need assistance, please signal a conference specialists by pressing the star key followed by 0.

After this morning's discussion, there will be an opportunity to ask questions. Please note that this event is being recorded.

I would now like to turn the conference call over to Mr. SAM Fish, Vero Inc.s executive director, investor relations and corporate communications. Please go ahead, sir.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------------------------------------------------------

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.